Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics

Pharmacogenomics

Volumn 6, Issue 2, 2005, Pages 139-149

  Lane, Hsien Yuan ^a   Lee, Cheng Chun ^a   Liu, Yi Ching ^a   Chang, Wen Ho ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Association; Atypical antipsychotics; Negative symptoms; Polymorphisms; Receptor; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; CYTOCHROME P450; CYTOSINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; GUANINE; NEUROTRANSMITTER RECEPTOR; NEW DRUG; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SERTINDOLE; SERTRALINE; THREONINE; ZIPRASIDONE; ZOTEPINE;

BODY WEIGHT DISORDER; COGNITION; COGNITIVE DEFECT; DELUSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; GENE CONTROL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HALLUCINATION; HUMAN; NONHUMAN; PHARMACOGENETICS; PREDICTION; PROTEIN FUNCTION; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 18144386142     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.2.139     Document Type: Review

References (94)

1. Andreasen NC, Flaum M, Swayze VW 2nd, Tyrrell G, Arndt S: Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch. Gen. Psychiatry 47, 615-621 (1990).
2. Toomey R, Kremen WS, Simpson JC et al.: Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Am. J. Psychiatry 154, 371-377 (1997).
3. Mueser KT, Douglas MS, Bellack AS, Morrison RL: Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr. Bull. 17, 565-582 (1991).
4. Cornblatt B, Obuchowski M, Andreasen A: Attention, clinical symptoms and pharmacology in schizophrenia. Schizophr. Res. 24, 212-213 (1997).
5. Meltzer HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(Suppl. 2), 106-115 (1999).
6. Chen WJ, Faraone SV: Sustained attention deficits as markers of genetic susceptibility to schizophrenia. Am. J. Med. Genet. 97, 52-57 (2000).
7. Staddon S, Arranz MJ, Mancama D, Mata I, Kerwin RW: Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 162, 18-23 (2002).
8. Scharfetter J: Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia. Pharmacogenomics 5, 691-698 (2004).
9. Hwu HG, Hong CJ, Lee YL, Lee PC, Lee SF: Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol. Psychiatry 44, 483-487 (1998).
10. Schafer M, Rujescu D, Giegling I et al.: Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am. J. Psychiatry 158, 802-804 (2001).
11. 2A receptor gene and the antipsychotic response to clozapine. Am. J. Psychiatry 153, 1092-1094 (1996).
12. Masellis M, Basile V, Meltzer HY et al.: Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19, 123-132 (1998).
13. Arranz MJ, Munro J, Birkett J et al.: Pharmacogenetic prediction of clozapine response. Lancet 355, 1615-1616 (2000).
14. Schumacher J, Schulze TG, Wienker TF, Rietschel M, Nothen MM: Pharmacogenetics of the clozapine response. Lancet 356, 506-507 (2000).
15. Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL: Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol. Psychiatry 47, 252-266 (2000).
16. Basile VS, Masellis M, Potkin SG, Kennedy JL: Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mol. Genet. 11, 2517-2530 (2002).
17. Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry 161, 780-796 (2004).
18. 2A receptor gene. Am. J. Psychiatry 159, 1593-1595 (2002).
19. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH: Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int. J. Neuropsychopharmacol. 7, 461-470 (2004).
20. 6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr. Res. 67, 63-70 (2004).
21. Zalsman G, Frisch A, Lev-Ran S et al.: DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur. Neuropsychopharmacol. 13, 183-185 (2003).
22. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 3, 356-361 (2003).
23. 2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J. Clin. Psychopharmacol. 22, 622-624 (2002).
24. 2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol. Bull. 37, 109-112 (2003).
25. Szekeres G, Keri S, Juhasz A et al.: Role of dopamine D3 receptor (DRD3) and dopamine transporter polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. 124B, 1-5 (2004).
26. Suhara T, Okubo Y, Yasuno F et al.: Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 59, 25-30 (2002).
27. Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 158, 360-369 (2001).
28. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55(Suppl. May), 5-12 (1994).
29. Vanhauwe JF, Ercken M, van de Wiel D, Jurzak M, Leysen JE: Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells. Psychopharmacology 150, 383-390 (2000).
30. 6 receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol. Biochem. Behav. 71, 635-643 (2002).
31. Tarazi FI, Zhang K, Baldessarini RJ: Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 161, 263-270 (2002).
32. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581-1589 (2003).
33. Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346, 16-22 (2002).
34. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45, 789-796 (1988).
35. Green MF, Marshall BD Jr, Wirshing WC et al.: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry 154, 799-804 (1997).
36. Bilder RM, Goldman RS, Volavka J et al.: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159, 1018-1028 (2002).
37. Rosenheck R, Cramer J, Xu W et al.: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N. Engl. J. Med. 337, 809-815 (1997).
38. Lieberman JA, Safferman AZ, Pollack S et al.: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry 151, 1744-1752 (1994).
39. Lane HY, Chiu WC, Chou JCY, Wu ST, Chiu CC, Chang WH: Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J. Clin. Psychiatry 61, 209-214 (2000).
40. Lane HY, Chang YC, Chiu CC, Lee SH, Lin CY, Chang WH: Fine-tuning risperidone dosage for acute schizophrenia: clinical determinants. Psychopharmacology 172, 393-399 (2004).
41. Lane HY, Chang WH, Chiu CC, Huang MC, Lee SH, Chen JY: A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia. J. Clin. Psychiatry 62, 994-995 (2001).
42. Montague PR, Hyman SE, Cohen JD: Computational roles for dopamine in behavioural control. Nature. 431, 760-767 (2004).
43. Matsumoto M, Togashi H, Mori K, Ueno K, Miyamoto A, Yoshioka M: Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. 383, 39-48 (1999).
44. Otano A, Frechilla D, Cobreros A et al.: Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine 6 receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience 92, 1001-1009 (1999).
45. 6 receptor antagonist Ro 04-6790 on learning consolidation. Behav. Brain. Res. 18, 107-110 (2001).
46. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J: Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry 51, 912-917 (1994).
47. Egan MF, Goldberg TE, Kolachana BS et al.: Effect of COMTVal108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98, 6917-6922 (2001).
48. Scordo MG, Spina E: Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3, 201-218 (2002).
49. Lane HY, Deng HC, Huang SM, Hu WH, Chang WH, Hu OYP: Low frequency of dextromethorphan O]i-demethylation deficiency in a Chinese population. Clin. Pharmacol. Ther. 60, 696-698 (1996).
50. Dahl ML: Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet. 41, 453-470 (2002).
51. Roses AD: Genome-based pharmacogenetics and the pharmaceutical industry. Nat. Rev. Drug Discov. 1, 541-549 (2002).
52. Bishop JR, Ellingrod VL: Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response. Pharmacogenomics 5, 463-477 (2004).
53. Weinshilboum R, Wang L: Pharmacogenomics: bench to bedside. Nat. Rev. Drug. Discov. 3, 739-748 (2004).
54. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5, 645-656 (2004).
55. Jablensky A: Resolving schizophrenia's CATCH22. Nat. Genet. 36, 674-675 (2004).
56. Arranz MJ, Munro J, Osborne S, Collier D Kerwin RW: Difficulties in replication of results. Lancet 356, 1359-1360 (2000).
57. Ambrose HJ: SNPs and pharmacogenomics Pharmacogenomics 3, 583-586 (2002).
58. Lieberman JA, Koreen AR, Chakos M et al.: Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiatry 57(Suppl. 9), 5-9 (1996).
59. Szymanski S, Lieberman J, Pollack S et al.: Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol. Psychiatry 39, 249-254 (1996).
60. Lane HY, Chang YC, Chiu CC, Chen TT, Lee SH, Chang WH: Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. J. Clin. Psychopharmacol. 22, 353-358 (2002).
61. Vanderzwaag C, McGee M, McEvoy Jp, Freudenreich O, Wilson WH, Copper TB: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am. J. Psychiatry 153, 1579-1584 (1996).
62. Perry PJ, Lund BC, Sanger T, Beasley C: Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial. J. Clin. Psychopharmacol. 21, 14-20 (2001).
63. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J. Clin. Psychiatry 60, 36-40 (1999).
64. Lane HY, Guo SC, Hwang TJ et al.: Olanzapine plasma levels and antidepressant effects in schizophrenic patients. J. Clin. Psychopharmacol. 22, 530-532 (2002).
65. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K: Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther. Drug Monit. 20, 380-384 (1998).
66. Spina E, Avenoso A, Facciola G et al.: Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153, 238-243 (2001).
67. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-27 (1987).
68. 2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. 67, 812-822 (2002).
69. 2A receptors and clozapine response. Schizophr. Res. 32, 93-99 (1998).
70. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ: Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 10, 1231-1233 (1999).
71. 6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr. Res. 47, 49-58 (2001).
72. 6) receptor gene in bipolar affective disorder and schizophrenia. Am. J. Med. Genet. 96, 217-221 (2000).
73. Itokawa M, Toru M, Ito K et al.: Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 49, 560-566 (1996).
74. Cravchik A, Sibley DR, Gejman PV: Functional analysis of the human D2 dopamine receptor missense variants. J. Biol. Chemistry 271, 26013-26017 (1996).
75. Arinami T, Itokawa M, Enguchi H et al.: Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 343, 703-704 (1994).
76. Parsons MJ, Mara I, Beperet M et al.: Association of a D2 receptor gene polymorphism with schizophrenia and treatment response in the Basque and Spanish populations. Am. J. Med. Genet 130B, 164 (2004) (Abstract).
77. Bertolino A, Caforio G, Blasi G et al.: Interaction of COMTVal108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161, 1798-1805 (2004).
78. Schwartz JC, Diaz J, Pilon C et al.: Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Rev. 31, 277-287 (2001).
79. Staddon S, English J, Lopez-Ilundain JM et al.: Allelic variations in CYP450 Enzymes and olanzapine response. Am. J. Med. Genet. 130B, 161 (2004) (Abstract).
80. Sachse C, Brockmoller J, Bauer S, Root I: Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445-449 (1999).
81. Green MF, Nuechterlein KH, Gold JM et al.: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56, 301-307 (2004).
82. Breier A: Cognitive deficit in schizophrenia and its neurochemical basis. Br. J. Psychiatry 174(Suppl. 37), 16-18 (1999).
83. Liu SK, Chen WJ, Chang CJ, Lin HN: Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology 22, 311-319 (2000).
84. Green MF, Marder SR, Glynn SM et al.: The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry 51, 972-978 (2002).
85. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH: Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia patients. J. Clin. Psychiatry 64, 316-320 (2003).
86. 2C receptor gene polymorphism. Lancet 359, 2086-2087 (2002).
87. 2C receptor gene and clozapine-induced weight gain. Am. J. Psychiatry 160, 677-679 (2003).
88. 2C receptor gene and their association with obesity and Type II diabetes. Diabetologia 43, 373-376 (2002).
89. 2C receptor and clozapine-induced weight gain. Lancet 360, 1790-1791 (2002).
90. 2C receptor and clozapine-induced weight gain. Lancet (2002) 360:1790.
91. Lane HY, Chang YC, Huang CL, Chang WH: Refining pharmacogenetic research in schizophrenia: control for patient-related variables. Drug Develop. Res. 60, 164-171 (2003).
92. Krebs MO, Guillin O, Bourdell MC et al.: Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol. Psychiatry 5, 558-562 (2000).
93. Pritchard JK, Rosenberg NA: Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 65, 220-228 (1999).
94. Devlin B, Roeder K: Genomic control for association studies. Biometrics 55, 997-1004 (1999).